Search

Ronnda L Bartel

from Ann Arbor, MI
Age ~66
Get Report
Also known as:
Ronna L Bartel, Ronnda Barteo, Ronnda Dartel, L Bartel
Phone and address:
330 Village Green Blvd, Ann Arbor, MI 48105
(734) 369-8487
Related to:
Vernon A Bartel, 92
Connected to:
Alex I Bartel, 47Alexandra L Bartel, 35Anita M Bartel, 77Anne B Bartel, 80Bethany A Bartel, 78Brett B Bartel, 46Carol J Bartel, 94Cathy A Bartel, 56Connie Bartel, 65Courtney C Bartel, 46

Ronnda Bartel Phones & Addresses

  • 330 Village Green Blvd, Ann Arbor, MI 48105 (734) 369-8487
  • 330 Village Green Blvd #102, Ann Arbor, MI 48105 (734) 369-8487
  • 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105
  • 9866 Mercy Rd, San Diego, CA 92129 (858) 547-9538
  • 9866 Mercy Rd #2, San Diego, CA 92129 (858) 547-9538
  • 11905 Wilmington Rd, San Diego, CA 92128
  • 9970 Erma Rd #140, San Diego, CA 92131
  • 3805 Knickerbocker Pkwy #F, Raleigh, NC 27612 (919) 571-3689
  • Sunnyvale, CA
  • 330 Village Green Blvd APT 1, Ann Arbor, MI 48105 (734) 369-8487

Work

Company: Aastrom biosciences 2010 Position: Chief scientific officer

Education

Degree: PhD School / High School: University of Kansas 1980 to 1984 Specialities: Biochemistry

Skills

Biotechnology • Biopharmaceuticals • Life Sciences • Commercialization • Lifesciences • Assay Development • Technology Transfer • Cell Biology • In Vitro • Cell Culture • Pharmaceutical Industry • Tissue Engineering • Gmp • Fda • Regenerative Medicine • Clinical Development • Drug Discovery • Drug Development • Cell • Clinical Trials • Biochemistry • Product Development • Research • Molecular Biology • Medical Devices • Validation • Immunology • Stem Cells • Elisa • R&D • Glp • Flow Cytometry • Cell Therapy • Sop • Iso 13485 • Microbiology • Science • Capa • Regulatory Submissions • Biomarkers • Research and Development • U.s. Food and Drug Administration • Cgmp • Oncology

Industries

Biotechnology

Resumes

Resumes

Ronnda Bartel Photo 1

Vice President, Product Development And Manufacturing

View page
Location:
24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105
Industry:
Biotechnology
Work:
Aastrom Biosciences since 2010
Chief Scientific Officer
Aastrom Biosciences 2006 - Apr 2010
VP Technical Operations
MicroIslet, Inc. 2004 - 2006
Executive Director
SRS Capital 2001 - 2002
Senior Director, Science and Technology
StemCells Inc 1998 - 2001
Vice President, Scientific Development
Education:
University of Kansas 1980 - 1984
PhD, Biochemistry
Skills:
Biotechnology
Biopharmaceuticals
Life Sciences
Commercialization
Lifesciences
Assay Development
Technology Transfer
Cell Biology
In Vitro
Cell Culture
Pharmaceutical Industry
Tissue Engineering
Gmp
Fda
Regenerative Medicine
Clinical Development
Drug Discovery
Drug Development
Cell
Clinical Trials
Biochemistry
Product Development
Research
Molecular Biology
Medical Devices
Validation
Immunology
Stem Cells
Elisa
R&D
Glp
Flow Cytometry
Cell Therapy
Sop
Iso 13485
Microbiology
Science
Capa
Regulatory Submissions
Biomarkers
Research and Development
U.s. Food and Drug Administration
Cgmp
Oncology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ronnda L. Bartel
Ronnda L Bartel Consulting, LLC
9866 Mercy Rd, San Diego, CA 92129

Publications

Us Patents

Compositions And Methods Of Treating No-Option Critical Limb Ischemia (Cli)

View page
US Patent:
20120100108, Apr 26, 2012
Filed:
Jun 10, 2011
Appl. No.:
13/158298
Inventors:
Ronnda Bartel - Ann Arbor MI, US
Sharon Watling - Ann Arbor MI, US
Assignee:
Aastrom Biosciences, Inc. - Ann Arbor MI
International Classification:
A61K 35/12
A61P 43/00
US Classification:
424 933
Abstract:
The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using a standard method of revascularization, i.e. a subject with “no-option” CLI. Methods of the invention include administering to a subject with no-option CLI an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the viability of said cells is at least 80% and the composition contains: a) about 5-75% viable CD90 cells with the remaining cells in said composition being CD45; b) less than 2 μg/ml of bovine serum albumin; c) less than 1 μg/ml of a enzymatically active harvest reagent; and d) substantially free of mycoplasma, endotoxin, and microbial contamination.

Mesenchymal Stromal Cell Populations And Methods Of Making Same

View page
US Patent:
20140193375, Jul 10, 2014
Filed:
May 18, 2012
Appl. No.:
14/117774
Inventors:
Frank Zeigler - Encinitas CA, US
Ronnda L. Bartel - San Diego CA, US
Assignee:
AASTROM BIOSCIENCES, INC. - Ann Arbor MI
International Classification:
A61K 35/28
US Classification:
424 937, 435325
Abstract:
The present invention provides compositions of mesenchymal stromal cells which express B7-H3, their subsequent use in tissue repair, improved methods of producing tissue repair cells and method of producing a substantially pure population of CD14+ autofluorescent macrophages.

Cd14+ Cell Compositions And Methods Of Using Same

View page
US Patent:
20140099292, Apr 10, 2014
Filed:
Sep 25, 2013
Appl. No.:
14/037030
Inventors:
- Ann Arbor MI, US
Ronnda L. Bartel - San Diego CA, US
Frank Zeigler - Encinitas CA, US
Assignee:
Aastrom Biosciences, Inc. - Ann Arbor MI
International Classification:
C12N 5/0786
US Classification:
424 9371, 435375, 435366
Abstract:
The present invention provides CD 14cell compositions and methods of using same in treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease.
Control profile
Ronnda L Bartel from Ann Arbor, MI, age ~66 Get Report